AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Fulcrum Therapeutics Soars 12.58% on Upgrade
Generated by AI AgentAinvest Pre-Market Radar
Monday, May 26, 2025 4:26 am ET1min read
Fulcrum Therapeutics' stock surged 12.58% in pre-market trading on May 26, 2025, marking a significant rise for the biopharmaceutical company.
Leerink Partners has upgraded
from a "market perform" rating to an "outperform" rating. This upgrade comes as the company's shares have declined by approximately 15% over the past year. The analyst, Joseph Schwartz, cited the potential for upcoming data on the company's lead product as a key factor in the upgrade.Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing new medicines by unlocking gene control mechanisms. The company's innovative approach to
has garnered attention from analysts, who see potential in its pipeline of treatments.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Metallus shares plunge 6.73% as investor concerns over earnings volatility and sector risks grow
Dec.22 2025
Annexon (ANNX) Surges 7.26% in Pre-Market Trading After S&P Biotechnology Index Inclusion
Dec.22 2025
Aeva Technologies Inc. surges 7.69% on strategic partnership with major automaker
Dec.22 2025
Oracle shares surge 6.63% on OpenAI rebuttal and healthcare contracts
Dec.22 2025
Broadcom Inc. (NASDAQ:AVGO) surges 3.18% on analyst upgrades amid AI growth optimism
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet